JP2012508274A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508274A5
JP2012508274A5 JP2011536383A JP2011536383A JP2012508274A5 JP 2012508274 A5 JP2012508274 A5 JP 2012508274A5 JP 2011536383 A JP2011536383 A JP 2011536383A JP 2011536383 A JP2011536383 A JP 2011536383A JP 2012508274 A5 JP2012508274 A5 JP 2012508274A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
independently
nitrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536383A
Other languages
English (en)
Japanese (ja)
Other versions
JP5432275B2 (ja
JP2012508274A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063020 external-priority patent/WO2010056563A1/en
Publication of JP2012508274A publication Critical patent/JP2012508274A/ja
Publication of JP2012508274A5 publication Critical patent/JP2012508274A5/ja
Application granted granted Critical
Publication of JP5432275B2 publication Critical patent/JP5432275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536383A 2008-11-11 2009-11-03 Aktおよびp70s6キナーゼ阻害剤 Active JP5432275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
US61/113,273 2008-11-11
PCT/US2009/063020 WO2010056563A1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012508274A JP2012508274A (ja) 2012-04-05
JP2012508274A5 true JP2012508274A5 (enExample) 2012-07-12
JP5432275B2 JP5432275B2 (ja) 2014-03-05

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536383A Active JP5432275B2 (ja) 2008-11-11 2009-11-03 Aktおよびp70s6キナーゼ阻害剤

Country Status (36)

Country Link
US (1) US8148387B2 (enExample)
EP (1) EP2358710B1 (enExample)
JP (1) JP5432275B2 (enExample)
KR (1) KR101334460B1 (enExample)
CN (1) CN102216302B (enExample)
AR (1) AR074072A1 (enExample)
AU (1) AU2009314324B2 (enExample)
BR (1) BRPI0921916A2 (enExample)
CA (1) CA2743019C (enExample)
CO (1) CO6382114A2 (enExample)
CR (1) CR20110240A (enExample)
CY (1) CY1113409T1 (enExample)
DK (1) DK2358710T3 (enExample)
DO (1) DOP2011000129A (enExample)
EA (1) EA018947B1 (enExample)
EC (1) ECSP11011048A (enExample)
ES (1) ES2391704T3 (enExample)
HN (1) HN2011001247A (enExample)
HR (1) HRP20120738T1 (enExample)
IL (1) IL211940A (enExample)
JO (1) JO2822B1 (enExample)
MA (1) MA32776B1 (enExample)
MX (1) MX2011005000A (enExample)
MY (1) MY161461A (enExample)
NZ (1) NZ592062A (enExample)
PA (1) PA8846901A1 (enExample)
PE (1) PE20110807A1 (enExample)
PL (1) PL2358710T3 (enExample)
PT (1) PT2358710E (enExample)
RS (1) RS52520B (enExample)
SI (1) SI2358710T1 (enExample)
TN (1) TN2011000207A1 (enExample)
TW (1) TWI422587B (enExample)
UA (1) UA100190C2 (enExample)
WO (1) WO2010056563A1 (enExample)
ZA (1) ZA201102549B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548970B (zh) 2009-07-02 2015-11-25 赛诺菲 新型(6-氧代-1,6-二氢嘧啶-2-基)酰胺衍生物、其制备方法以及其作为akt(pkb)磷酸化抑制剂的医药用途
KR101398268B1 (ko) * 2009-10-23 2014-05-23 일라이 릴리 앤드 캄파니 Akt 억제제
PL2694510T3 (pl) 2011-04-07 2016-03-31 Bayer Ip Gmbh Imidazopirydazyny jako inhibitory kinazy Akt
US8927572B2 (en) * 2011-07-09 2015-01-06 Xuanzhu Pharma Co., Ltd. Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof
ES2644536T3 (es) * 2011-09-12 2017-11-29 Merck Patent Gmbh Imidazol-aminas novedosas como moduladores de la actividad cinasa
JP6082011B2 (ja) 2011-09-12 2017-02-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung キナーゼ活性のモジュレーターとして使用するためのアミノピリミジン誘導体
ES2620119T3 (es) 2012-11-16 2017-06-27 Merck Patent Gmbh Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
ES2807539T3 (es) 2012-11-16 2021-02-23 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
AR095202A1 (es) * 2013-03-11 2015-09-30 Merck Patent Gmbh Heterociclos como moduladores de la actividad quinasa
RU2690679C2 (ru) * 2014-02-11 2019-06-05 Мерк Патент Гмбх Новые пиримидинимидазоламины в качестве модуляторов активности киназы
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
AU2017265769B9 (en) 2016-05-20 2019-05-30 Taiho Pharmaceutical Co., Ltd. Novel 5H-Pyrrolo(2,3-D)Pyrimidin-6(7H)-one derivative
CA3167999A1 (en) 2020-03-17 2021-09-23 Xin Li Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
JP2024535857A (ja) 2021-09-17 2024-10-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 縮合二環系誘導体の薬学的に許容される塩、結晶及びそれらの調製方法
EP4553078A1 (en) * 2022-07-05 2025-05-14 Taiho Pharmaceutical Co., Ltd. 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006071819A1 (en) 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
FI3719018T3 (fi) 2006-04-25 2025-10-07 Astex Therapeutics Ltd Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Similar Documents

Publication Publication Date Title
JP2012508274A5 (enExample)
HRP20120738T1 (hr) Inhibitori kinaza akt i p70 s6
JP2007533741A5 (ja) Bace阻害剤として有用なピロリジン誘導体
JP2016516043A5 (enExample)
JP2011507849A5 (enExample)
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
JP2013531055A5 (enExample)
JP2018519323A5 (enExample)
JP2009516697A5 (enExample)
JP2011512412A5 (enExample)
JP2010538076A5 (enExample)
JP2008536825A5 (enExample)
JP2015501799A5 (enExample)
MX2007005189A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3.
JP2011513305A5 (enExample)
JP2014526549A5 (enExample)
JP2011502958A5 (enExample)
JP2008520742A5 (enExample)
JP2005510473A5 (enExample)
MX2009004715A (es) Compuestos heterociclicos como agentes antiinflamatorios.
JP2013530240A5 (enExample)
JP2012530765A5 (enExample)
JP2016513681A5 (enExample)
JP2017538773A5 (enExample)
JP2010155827A5 (enExample)